Today: 7 February 2026
Subscribe
Browse Category

NYSE:JNJ News 27 December 2025 - 6 January 2026

Johnson & Johnson stock ticks up on lupus drug data as earnings loom

Johnson & Johnson stock ticks up on lupus drug data as earnings loom

Johnson & Johnson shares rose 0.5% to $205.41 midday Tuesday after reporting positive Phase 2b results for its lupus drug nipocalimab and announcing plans for Phase 3 trials. The company also filed in Europe to expand use of its myeloma drug combo Tecvayli and Darzalex. J&J continues to face pressure from ongoing talc litigation, with more trials expected this year.
6 January 2026
···
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie shares closed down 4% at $220.18 on Monday, underperforming a market rally that sent the Dow to a record. Trading volume reached 8.9 million shares, well above the 50-day average. The stock now sits below key technical levels ahead of its Jan. 14 presentation at the J.P. Morgan Healthcare Conference and expected late-January earnings.
6 January 2026
·····
Johnson & Johnson stock slips despite fresh bullish calls — what investors watch before earnings

Johnson & Johnson stock slips despite fresh bullish calls — what investors watch before earnings

Johnson & Johnson shares fell 1.47% to $204.31 Monday, underperforming the S&P 500’s 0.64% gain. UBS reiterated a Buy rating but lowered earnings forecasts after management warned of about $0.20 adjusted EPS dilution from the Halda Therapeutics acquisition. J&J will present at the JPMorgan Healthcare Conference Jan. 12 and report Q4 results Jan. 21.
6 January 2026
··
JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

Johnson & Johnson shares dropped 2.2% to $202.86 Monday, underperforming a rising market as investors rotated out of healthcare stocks. The move comes ahead of key events including the Jan. 9 U.S. jobs report and J&J’s Jan. 21 earnings call. More than 67,000 talc lawsuits remain unresolved, with a special master set to review expert evidence in New Jersey federal court.
5 January 2026
···
Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

U.S. drugmakers are raising list prices on at least 350 branded medicines for 2026, with a median increase of about 4%, Reuters reported. The Health Care Select Sector SPDR Fund (XLV) closed up 0.46% at $155.51 Friday. Pfizer, Eli Lilly, and Johnson & Johnson all posted gains. Traders are watching next week’s U.S. jobs data and upcoming healthcare earnings.
3 January 2026
····
Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson closed Friday up 0.19% at $207.35 after declaring a $1.30-per-share quarterly dividend, payable March 10 to shareholders of record as of Feb. 24. The stock traded between $203.68 and $207.37 during the session. Investors await J&J’s Jan. 21 earnings call and next week’s U.S. labor data. The S&P 500 finished up 0.19%.
3 January 2026
·····
Johnson & Johnson stock holds near $207 as New Year’s Day shuts U.S. markets — what to watch next

Johnson & Johnson stock holds near $207 as New Year’s Day shuts U.S. markets — what to watch next

Johnson & Johnson shares closed up 0.02% at $206.95 on Wednesday, ahead of the New Year’s Day market holiday. The company completed its $3.05 billion acquisition of Halda Therapeutics and plans to appeal a $1.5 billion talc verdict. Drugmakers are set to raise list prices on at least 350 medicines in 2026, Reuters reported. J&J’s fourth-quarter earnings call is set for Jan. 21.
1 January 2026
·
Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target

Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target

Johnson & Johnson closed its $3.05 billion acquisition of Halda Therapeutics, saying the deal will cut adjusted EPS by $0.20 between late 2025 and 2026. JNJ shares edged up 0.02% to $206.95 as the S&P 500 fell 0.74% on the year’s final trading day. Barclays raised its price target to $217, maintaining an Equal Weight rating. The company will discuss its 2026 outlook on Jan. 21.
1 January 2026
··
JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

NEW YORK, December 30, 2025, 18:51 ET — After-hours Johnson & Johnson (JNJ) shares edged lower in after-hours trading on Tuesday after the healthcare conglomerate said it had completed its acquisition of Halda Therapeutics. The stock was down 0.3% at $206.91. The completion matters because investors are resetting portfolios into year-end with interest rates back in focus and dealmaking under a brighter spotlight. For J&J, the question is whether a new oncology platform can expand its pipeline without pressuring near-term profit metrics. The timing also pushes the spotlight onto management’s next set of targets. With the company set to talk
31 December 2025
··
Johnson & Johnson stock today: JNJ slips after $3.05B Halda cancer deal closes, Barclays lifts target

Johnson & Johnson stock today: JNJ slips after $3.05B Halda cancer deal closes, Barclays lifts target

NEW YORK, December 30, 2025, 12:44 ET — Regular session Johnson & Johnson shares edged lower on Tuesday after the company said it completed its $3.05 billion cash purchase of cancer-therapy developer Halda Therapeutics. The stock was down about 0.2% at $207.12 in midday trading. Executive vice president Jennifer Taubert called the closing a “strategic milestone” as J&J flagged about $0.20 of dilution to adjusted earnings per share — profit per share excluding certain one-time items — split between 2025 and 2026. Johnson & Johnson Investor Relations The closing gives J&J a new platform aimed at developing oral, targeted cancer
30 December 2025
··
JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

NEW YORK, December 29, 2025, 20:26 ET — Market closed Johnson & Johnson (JNJ) shares were last down 0.02% at $207.56 on Monday after the healthcare conglomerate said it completed its $3.05 billion cash acquisition of cancer drug developer Halda Therapeutics. The stock traded between $207.31 and $209.46, and J&J said it will account for the deal as a business combination and expects it to cut adjusted earnings per share by about $0.20, split evenly between the fourth quarter and 2026. JNJ.com The closing matters because it adds another pipeline bet in oncology, where big drugmakers are still hunting for
30 December 2025
····
JNJ stock edges higher after Johnson & Johnson closes $3.05B Halda deal; earnings outlook next

JNJ stock edges higher after Johnson & Johnson closes $3.05B Halda deal; earnings outlook next

NEW YORK, December 29, 2025, 14:38 ET — Regular session Johnson & Johnson shares were up about 0.3% at $208.28 in afternoon trading on Monday after the healthcare conglomerate said it had completed its $3.05 billion cash acquisition of Halda Therapeutics. JNJ.com The close matters because it brings Johnson & Johnson a clinical-stage oncology platform and assets as investors press large drugmakers to keep replenishing their pipelines ahead of patent expirations and pricing pressure. It also puts the focus back on execution: the deal is expected to dent near-term profit metrics, and Johnson & Johnson has flagged its next earnings
29 December 2025
···
Dow slips from record close as tech rally cools in year-end trade

Dow slips from record close as tech rally cools in year-end trade

NEW YORK, December 29, 2025, 10:30 ET — Regular session. The Dow Jones Industrial Average slipped on Monday as heavyweight technology shares gave back some of last week’s gains, pulling the blue-chip index off its recent highs. By 9:35 a.m. ET, the Dow was down 66.86 points, or 0.14%, at 48,645.62. Reuters The move matters because the final week of the year typically brings lighter trading volume, which can exaggerate swings. U.S. markets will be closed on Thursday for New Year’s Day, and traders expect holiday-affected conditions to keep activity thin. Reuters Investors have also been eyeing whether the late-year
29 December 2025
······
Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

NEW YORK, Dec. 28, 2025, 3:26 p.m. ET — Market closed Johnson & Johnson stock (NYSE: JNJ) heads into the final trading week of 2025 with U.S. markets shut for the weekend and investors sorting through a fresh pipeline headline that surfaced late Friday. With the New York Stock Exchange closed today and the next regular session set for Monday, Dec. 29, attention is shifting to what could move JNJ when trading resumes—including biotech read-throughs, litigation headlines, and year-end macro catalysts in a holiday-shortened week. New York Stock Exchange+2Investopedia+2 As of the latest available market data, JNJ last traded around
28 December 2025
··
Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

NEW YORK, Dec. 27, 2025, 3:33 PM ET — Market closed Johnson & Johnson (NYSE: JNJ) stock is heading into the final trading days of 2025 with U.S. markets closed for the weekend and year-end liquidity typically thinning across Wall Street. JNJ last closed at $207.63 on Friday, down 0.07% on the day, and was last indicated around $207.86 in after-hours trading, according to widely followed market data. Investing.com+1 For investors, the key question before Monday’s open is whether the latest company-specific headline—a discontinued mid-stage eczema (atopic dermatitis) trial—changes the near-term narrative for a stock that has been trading in
27 December 2025
··
Healthcare Stocks Outlook: Year-End Rotation, J&J’s Eczema Setback, and Managed-Care Scrutiny Shape the Setup Before Monday’s Open

Healthcare Stocks Outlook: Year-End Rotation, J&J’s Eczema Setback, and Managed-Care Scrutiny Shape the Setup Before Monday’s Open

NEW YORK, Dec. 27, 2025, 12:57 p.m. ET — Market closed (weekend) Healthcare stocks are heading into the final trading days of 2025 with a rare mix of “defensive” support and headline-driven volatility—exactly the combination that can matter most when liquidity is thin and investors are rebalancing portfolios into year-end. U.S. stock markets are shut today, but Friday’s post-Christmas session left a clear message: the broader market is still hovering near record levels, and investors have been widening their focus beyond mega-cap technology—an environment that can favor large-cap healthcare even as biotech remains more catalyst-sensitive. Reuters+1 Where healthcare stocks stand
27 December 2025
1 2 3 4 5 6 7

Stock Market Today

Energy stocks set for a geopolitical week after Iran warning and oil rebound

Energy stocks set for a geopolitical week after Iran warning and oil rebound

7 February 2026
U.S. energy stocks rose Friday, with the S&P 500 energy sector up 1.88% and Exxon Mobil gaining 2.03%. Brent crude settled at $68.05 a barrel after Iran threatened U.S. bases if attacked. Saudi Aramco cut March Arab Light crude prices to a five-year low for Asia. Kazakhstan’s CPC Blend exports may drop 35% this month due to Tengiz oilfield disruptions.
Financial services stocks rally as XLF jumps, Dow hits 50,000 — what to watch next week

Financial services stocks rally as XLF jumps, Dow hits 50,000 — what to watch next week

7 February 2026
U.S. financial stocks rose Friday, with the XLF fund up 1.8% and the Dow closing above 50,000 for the first time, gaining 2.47%. Goldman Sachs jumped 4.3%, JPMorgan 3.9%, and Citigroup 6.0%. The Federal Reserve held rates steady, and San Francisco Fed President Mary Daly signaled possible cuts this year. Investors await January jobs and inflation data next week.
Go toTop